Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems.
about
Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles.Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.Quantifying exploratory low dose compounds in humans with AMS.Granulated colloidal silicon dioxide-based self-microemulsifying tablets, as a versatile approach in enhancement of solubility and therapeutic potential of anti-diabetic agent: formulation design and in vitro/in vivo evaluation.Strategies to improve oral drug bioavailability.Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs.Gender: a possible determinant in dosing of dermatologic drugs--an overview.Modeling free energies of solvation in olive oil.Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea.A toxicity assessment of 30 pharmaceuticals using Aliivibrio fischeri: a comparison of the acute effects of different formulations.
P2860
Q33642023-EDF13185-0573-48F3-8437-03B243B54089Q34562249-4A759DE2-35B0-4BB1-AE25-F95994FA7F69Q34708648-2A855383-7283-4972-B906-12AA502AD24CQ36301891-0BD03AB1-2EE4-456E-82A0-37845B3B64ABQ36316751-B1E3E71B-93F5-4A9B-8900-9AB2280782D7Q36349701-2AE5B14E-FDA4-4EA8-B205-EEF03F43203CQ36596188-675EA6AD-98C5-4AE5-8FC0-A27C6852F10BQ37409430-370B9C84-AF3B-4551-903F-81D14855ED5CQ38115195-02B757B1-6F84-4DD6-BB10-07483CAF10EEQ38383531-C93E5626-0ADB-4C84-A189-D6F3A34A15AFQ42627966-312CF863-580F-4C0A-89C3-A040AEBDFDD1Q43245682-60474312-DC93-4706-92E1-77BF2B92E767Q43346983-44B45D41-E9B2-43F2-B459-3AE8AAB63058
P2860
Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Formulation and physiological ...... d-based drug delivery systems.
@ast
Formulation and physiological ...... d-based drug delivery systems.
@en
Formulation and physiological ...... d-based drug delivery systems.
@nl
type
label
Formulation and physiological ...... d-based drug delivery systems.
@ast
Formulation and physiological ...... d-based drug delivery systems.
@en
Formulation and physiological ...... d-based drug delivery systems.
@nl
prefLabel
Formulation and physiological ...... d-based drug delivery systems.
@ast
Formulation and physiological ...... d-based drug delivery systems.
@en
Formulation and physiological ...... d-based drug delivery systems.
@nl
P2860
P356
P1476
Formulation and physiological ...... d-based drug delivery systems.
@en
P2093
P2860
P304
P356
10.1081/DDC-100103726
P407
P577
2001-04-01T00:00:00Z